Abivax Provides Operational and Key Program Update
15 juil. 2024 16h00 HE
|
Abivax
Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1...
Sitryx announces leadership transition
02 juil. 2024 07h00 HE
|
Sitryx Therapeutics
Sitryx announces leadership transition Iain Kilty appointed Chief Executive Officer Neil Weir to assume role of President and remain on Board of Directors Oxford, UK – 2 July 2024 – Sitryx...
Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting
04 juin 2024 16h10 HE
|
Abivax
PARIS, France, June 4, 2024 – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the...
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
15 mai 2024 08h35 HE
|
ZyVersa Therapeutics
ZyVersa is on track to achieve key development milestones over the next 3 quarters.
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
08 mai 2024 02h30 HE
|
Abivax
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024 PARIS, France, May 8, 2024, 8:30 a.m. CEST –...
Abivax reports 2023 financial results and operational update
02 avr. 2024 02h30 HE
|
Abivax
Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and...
Sitryx Therapeutics makes key appointments to strengthen business operations and progress immunometabolism-targeting pipeline into clinical development
04 mars 2024 07h00 HE
|
Sitryx Therapeutics
Sitryx Therapeutics makes key appointments to strengthen business operations and progress immunometabolism-targeting pipeline into clinical development Ben Stephens brings seasoned operational and...
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
02 févr. 2024 02h30 HE
|
Abivax
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease Obefazimod Crohn’s Disease (CD) IND filed with the FDA in December...
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
24 janv. 2024 02h30 HE
|
Abivax
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024 PARIS,...
ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All Access
10 janv. 2024 08h06 HE
|
ZyVersa Therapeutics
View ZyVersa Therapeutics' Benzinga All Access Interview To Learn About Key Development Milestones in 2024.